S100A7 attenuates immunotherapy by enhancing immunosuppressive tumor microenvironment in lung squamous cell carcinoma  

作　　者：Chengming Liu Sufei Zheng Zhiliang Lu Zhanyu Wang Sihui Wang Xiaoli Feng Yan Wang Nan Sun Jie He 

机构地区：[1]Department of Thoracic Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,100021,Beijing,China [2]Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,100021,Beijing,China [3]Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,100021,Beijing,China

出　　处：《Signal Transduction and Targeted Therapy》2022年第11期4025-4027,共3页信号转导与靶向治疗（英文）

基　　金：National Natural Science Foundation of China(grant numbers 32170923,82103011);Beijing Natural Science Foundation(grant number 7214248);CAMS Innovation Fund for Medical Sciences(grant number 2021-I2M-1-050);Youth Elite Scientists Sponsorship Program by CAST(grant number 2019QNRC001);Beijing Nova Program of Science and Technology(grant number Z191100001119049).

摘　　要：Dear Editor,In recent years,the rapid development of immunotherapy has brought survival benefits for lung squamous cell carcinoma(LUSC)patients who have rare treatment options.Nevertheless,there are still some patients with immunotherapy resistance,which is the root cause of the low benefit rate and disease progression of the overall population,and it is an urgent problem to be solved.Except for tumor mutation burden,the tumor immune microenvironment(TIME)as characterized by infiltration of CD8+tumor-infiltrating lymphocytes(TILs)and PD-L1 expression has been associated with the efficacy of immune checkpoint inhibitors(ICIs).In our previous studies,we have demonstrated that psoriasin,also known as S100 calcium-binding protein A7(S100A7),not only accelerates tumor progression via the activation of the p-Erk pathway in LUSC and the p-Erk and p-FAK pathways in esophageal squamous cell carcinomas(ESCC)but also remodels the tumor microenvironment by promoting angiogenesis and M2 macrophage infiltration in ESCC.1,2 However,the role of S100A7 in the TIME and immunotherapy efficacy in LUSC remains to be elucidated.

关 键 词：S100A7 IMMUNOTHERAPY SQUAMOUS 

分 类 号：R734.2[医药卫生—肿瘤] R730.51[医药卫生—临床医学]